Search

Displaying results 4181 - 4190 of 7452 in total
  1. Drug

    Combretastatin

    go.drugbank.com/drugs/DB12596
    Investigational

    Combretastatin has been investigated for the treatment of Anaplastic Thyroid Cancer.

  2. Drug

    D-Leucine

    go.drugbank.com/drugs/DB01746
    Experimental

    An essential branched-chain amino acid important for hemoglobin formation. [PubChem]

  3. Drug

    Bunamidine

    go.drugbank.com/drugs/DB11501
    ExperimentalVet approved

    Bunamidine is a veterinary anti-platyhelmintic agent used for taenia infestations.

  4. Drug

    Belotecan

    go.drugbank.com/drugs/DB12459
    Investigational

    Belotecan has been investigated for the treatment of Epithelial Ovarian Cancer.

  5. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as [ISS-1018]), for use with its vaccine.

  6. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  7. Drug

    Protirelin

    go.drugbank.com/drugs/DB09421
    Approved

    Protirelin is the pharmaceutically available synthetic analogue of the endogenous peptide thyrotropin-releasing hormone (TRH). It is a tri-peptide tropic hormone, released by the hypothalamus, that stimulates the release of Thyroid Stimu...

    Categories: Tests for Thyreoidea Function
  8. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have … [A199122] Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  10. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency